aTyr Pharma Inc (NASDAQ:LIFE) has been downgraded to Hold in a statement by Zacks Investment Research earlier today.
- Updated: October 11, 2016
Having a price of $2.89, aTyr Pharma Inc (NASDAQ:LIFE) traded -4.93% lower on the day. With the last close down -10.79% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the same period. aTyr Pharma Inc has recorded a 50-day average of $3.12 and a two hundred day average of $3.24. Volume of trade was down over the average, with 71,419 shares of LIFE changing hands under the typical 223,246
Zacks Investment Research has downgraded aTyr Pharma Inc (NASDAQ:LIFE) to Hold in a statement released on Wednesday October 12, 2016.
On 8/16/2016, Zacks Investment Research released a statement on aTyr Pharma Inc (NASDAQ:LIFE) upped the target price from $0.00 to $4.00 that suggested an upside of 0.23%.
With a total market value of $0, aTyr Pharma Inc has with a one year low of $2.48 and a one year high of $13.26 .
A total of 3 analysts have released a report on aTyr Pharma Inc. zero analysts rating the company a strong buy, zero analysts rating the company a buy, zero analysts rating the company a hold, zero analysts rating the company a underperform, and finally zero analysts rating the company a sell with a 12-month price target of $30.67.
More About aTyr Pharma Inc (NASDAQ:LIFE)
aTyr Pharma, Inc. is a clinical-stage biotherapeutics company. The Company is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its Physiocrine biology, a discovered set of physiological modulators. The Company focuses on the development of Physiocrine-based therapeutics for the treatment of rare diseases, including facioscapulohumeral muscular dystrophy (FSHD) and limb-girdle muscular dystrophy (LGMD) 2B. The Company is developing Resolaris, an intravenous protein therapeutic for the treatment of rare myopathies with an immune component (RMICs). The Company is investigating Resolaris in patients with LGMD2B. The Company is conducting approximately three open label trials in patients with early onset FSHD, in adult patients with FSHD or LGMD2B and a long-term extension study in adult patients with FSHD. The Company has not generated any revenues.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.